Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk
![]() |
Cho, Yun-Kyeong
(Department of Internal Medicine, Keimyung University Dongsan Hospital)
Hur, Seung-Ho (Department of Internal Medicine, Keimyung University Dongsan Hospital) Han, Chun-Duk (Department of Internal Medicine, Keimyung University Dongsan Hospital) Park, Hyoung-Seob (Department of Internal Medicine, Keimyung University Dongsan Hospital) Yoon, Hyuck-Jun (Department of Internal Medicine, Keimyung University Dongsan Hospital) Kim, Hyung-Seop (Department of Internal Medicine, Keimyung University Dongsan Hospital) Nam, Chang-Wook (Department of Internal Medicine, Keimyung University Dongsan Hospital) Kim, Yoon-Nyun (Department of Internal Medicine, Keimyung University Dongsan Hospital) Kim, Kwon-Bae (Department of Internal Medicine, Keimyung University Dongsan Hospital) Park, Nam-Hee (Department of Thoracic and Cardiovascular Surgery, Keimyung University Dongsan Hospital) Park, Hee-Jun (Department of Medical Informatics, Keimyung University Dongsan Hospital) |
1 | Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. DOI ScienceOn |
2 | Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979;90:85-91. DOI ScienceOn |
3 | Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. DOI ScienceOn |
4 | Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283: 157-63. |
5 | Van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH 58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129: 1748-54. DOI ScienceOn |
6 | Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34. DOI ScienceOn |
7 | Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with si-mvastatin in patients with primary hypercholesterolemia: a randomiz-ed, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79: 620-9. DOI ScienceOn |
8 | Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:23-33. DOI ScienceOn |
9 | Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. DOI ScienceOn |
10 | Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-73. DOI ScienceOn |
11 | Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005-16. DOI ScienceOn |
12 | Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocar-dial Infarction 22 trials). Am J Cardiol 2007;100:1047-51. DOI ScienceOn |
13 | American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007;30(Suppl 1):S4-41. |
14 | Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94. DOI ScienceOn |
15 | Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006;81:1579-88. DOI ScienceOn |
16 | Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32. DOI ScienceOn |
17 | Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-78. DOI ScienceOn |
18 | Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:746-55. DOI ScienceOn |
19 | Yun KH, Park HY, Choi JH, et al. Comparison of efficacy and safety after administering high potency statin to high risk patients: rosuvastatin 10 mg versus atorvastatin 20 mg. Korean Circ J 2007;37:154-60. DOI ScienceOn |
![]() |